HOMEPAGE
Fully Diluted Subscribe

Nasdaq · Biotech stocks database

CPIX — Cumberland Pharmaceuticals Inc.

CPIX (Cumberland Pharmaceuticals Inc.) stock: $5.22, $78.2M market cap, $3.9M cash, $74.3M EV, $81.7M fully diluted market cap. Data from Fully Diluted's biotech stocks database.

What they do

THE COMPANY Cumberland Pharmaceuticals Inc. ("Cumberland," the "Company," or as used in the context of "we," "us" or "our"), is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription pharmaceuticals.

Source: 10-K FY2025 via SEC EDGAR

Share price
$5.22
Market cap
$78.2M
Cash
$3.9M
Enterprise value
$74.3M

Balance sheet

Cash$3.9M
Debt$0.0M
Net cash$3.9M
Enterprise value$74.3M
Basic shares15.0M shares
Fully diluted shares15.7M shares
Fully diluted market cap$81.7M
Cash per share$0.26
Quarterly burn+$0.2M generated

Cash figures as of 2026-06-30. Database snapshot: 2026-11-07.

Share structure

Common
15.0M
Pre-funded warrants
0.0M
Options
0.7M
RSUs
0.0M
Warrants
0.0M
Converts
0.0M
Conv preferred
0.0M
ESPP reserve
0.0M
FDSO
15.7M

Cap table as of 2026-06-30.

Price history

Loading CPIX daily closes…

Loading price history…

Next catalyst

Ifetroban Sodium · Feb 12 - Mar 25 in 15 mo · Phase 2 · Idiopathic Pulmonary Fibrosis

Recently reported

Oral Ifetroban Phase 2 Mixed · 2026-10-23
scleroderma, diffuse, scleroderma, systemic, scleroderma, limited
Primary: Safety of oral ifetroban in patients with systemic sclerosis, evaluated by the frequency of treatment emergent adverse events between treatment groups in the 12-month Phase 2a ASSIST-SSc trial (NCT02682511) — Ifetroban was well tolerated in patients with systemic sclerosis
· 31 subjects received ifetroban (22 with diffuse cutaneous SSc and 9 with SSc-PAH) and 10 subjects received placebo (9 dcSSc and 1 SSc-PAH)
· The Phase 2a trial was not designed or powered to evaluate efficacy, and limited disease progression in both groups reduced the ability to detect a treatment difference, so no efficacy conclusions were drawn
· Gastrointestinal adverse events were more frequent in the ifetroban group than in the placebo group; the majority were mild and resolved
· A modest increase in bleeding-related adverse events was observed with ifetroban, and these events were predominantly mild
· No serious adverse event during the 12-month treatment period was assessed by the medical monitor as related to study drug
· Next steps: submit the clinical study report to the FDA, complete correlative biomarker studies, and evaluate cardiac imaging from patients continuing on the open-label extension
Safety: Ifetroban was generally well tolerated, with a safety profile consistent with prior experience; gastrointestinal and bleeding-related adverse events were more frequent than placebo but mostly mild, and no serious adverse event was assessed as related to study drug
Source release →
Get the weekly biotech catalyst rundown.
Cash runways, financings, and trial readouts for all 721 stocks.
Subscribe to Compounding Ego